glaucoma. And Ocular Hypertension and treatment

hannahkwakye90 15 views 22 slides Oct 14, 2024
Slide 1
Slide 1 of 22
Slide 1
1
Slide 2
2
Slide 3
3
Slide 4
4
Slide 5
5
Slide 6
6
Slide 7
7
Slide 8
8
Slide 9
9
Slide 10
10
Slide 11
11
Slide 12
12
Slide 13
13
Slide 14
14
Slide 15
15
Slide 16
16
Slide 17
17
Slide 18
18
Slide 19
19
Slide 20
20
Slide 21
21
Slide 22
22

About This Presentation

About the eye
There increase ocular pressure


Slide Content

GLAUCOMA

Introduction
Glaucoma refers to a collection of diseases whereby increased intraocular
pressureadversely impacts the optic nerve, and subsequently, the visual field. 1
Normal Tension Glaucoma-Normal IOP (10-21mmHg)
Have in common a characteristic progressive optic neuropathy
Eventual development of distinctive irreversible structural and functional visual
dysfunction

Cassonet al 2012
“agroupofoculardisordersofmultifactorialaetiologyunitedbyaclinically
characteristicopticneuropathywithpotentiallyprogressive,clinicallyvisiblechanges
attheopticnervehead(ONH),comprisingfocalorgeneralizedthinningofthe
neuroretinalrimwithexcavationandenlargementoftheopticcup,representing
neurodegenerationofretinalganglioncellaxonsanddeformationofthelamina
cribrosa;correspondingdiffuseandlocalizednerve-fibre-bundlepattern,visualfield
lossmaynotbedetectableinearlystages;whilevisualacuityisinitiallyspared,
progressioncanleadtocompletelossofvision;theconstellationofclinicalfeatures
isdiagnostic”.2

Epidemiology
Third leading cause of blindness (<3/60)
Fourth leading cause of all vision loss worldwide
Leading cause of irreversible vision loss. 3
Global prevalence 2.2-3.54% (40-80yrs). 4,5
19.4 percent ofblindness (<3/60) in Ghana. 6
76 million -2020.
122 million –2040. 5
2381 new cases of glaucoma out of 19445 OPD attendance at the eye clinic -
12.24%.

Two main class
1.Open –Angle Glaucoma
2.Close –Angle Glaucoma
It can be
Primary
Secondary
Common –Primary Open Angle Glaucoma (POAG)

Pathophysiology

Pathophysiology

Mechanical theory
elevated IOP leads to the compression of the nerve fibrebundle
Ischemic / Vascular theory
Hemodynamic alterations may act independently from, or in conjunction with,
raised IOP to cause damage at the site of the ONH

Glaucoma continuum

Symptoms
POAG is asymptomatic in its early stage
Visual field loss starts from the periphery to central
Can lead to complete loss of vision

Risk Factors
High Intraocular Pressure (>21mmHg)*
Ethnicity –Africans (4.2%), Europeans (2.1%), Asian (1.4%)7
Increasing age (>40yrs).
Positive family Hxof glaucoma
Refractive Status-high myopia
Central corneal thickness
Diabetes and Hypertension –weak association

Diagnosis-workup
Funduscopy
Gonioscopy*
Tonometry
Optical coherence tomography (OCT)
Visual field Test (VFT)
Pachymetry*

Management
Medication
Beta blockers –reduce production
Alpha agonist -reduce production
Carbonic Anhydrous Inhibitors -reduce production
Cholinergic Agonist –increase drainage
Prostaglandin analogues –increase drainage

Surgery
-Trabeculectomy
-SIGS/ MIGS
-Glaucoma Implant Surgery

Laser
-Trabeculoplasty
-Iridotomy

CONCLUSION
The statistic are not good
Enormous Global financial burden-Global cost of productivity losses
$244 billion –uncorrected myopia
$25.4 billion –presbyopia
(WHO FACTS SHEET)

1.NavidMahabadi; Lisa A. Foris; KoushikTripathy. Open Angle Glaucoma,
StatPearlsPublishing; 2022 Jan
2.CassonR, ChidlowG, Wood J, CrowstonJ, Goldberg I (2012) Definition of
glaucoma: clinical and experimental concepts. ClinExpOphthalmol40:341–
349. doi:10.1111/j.1442-9071.2012.02773.x
3.WHO, fact sheets, blindness and vision impairment 14 Oct 2021
4.Genetics of glaucoma. WiggsJL, Pasquale LR.Hum MolGenet.2017;26:0.
5.Yih-Chung Tham,Xiang Li,Tien Y Wong,Harry A Quigley,Tin Aung,Ching-Yu
Cheng, Global prevalence of glaucoma and projections of glaucoma burden
through 2040 a systemic review and meta-analysis. Ophthalmology 2014; 121:
2081-2090
6.Ghana Blindness and Visual Impairment Study 2015; 25
7.Leske, M.C Open-Angle Glaucoma-An epidemiologic overview, ophthalmic
epid, 2007 14(4); p 166-172

Thank You